Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 16/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12594323 | 0.91 | GCK (0.46) | GCKKCNH2 | |
| SCHEMBL2664272 | 0.84 | GCK (0.45) | GCKPTGS2 | |
| SCHEMBL2668108 | 0.83 | GCK (0.47) | GCKPTGS2 | |
| SCHEMBL2668121 | 0.81 | GCK (0.43) | GCKPTGS2 | |
| SCHEMBL1107719 | 0.79 | MEN1 (0.58) | GCKPTGS2HAO1 | |
| SCHEMBL2664277 | 0.75 | GCK (0.39) | GCK | |
| SCHEMBL1107611 | 0.74 | MEN1 (0.52) | GCKPTGS2 | |
| SCHEMBL2654925 | 0.74 | MEN1 (0.49) | GCKPTGS2HAO1 | |
| SCHEMBL9891693 | 0.74 | MEN1 (0.49) | GCKPTGS2HAO1 | |
| SCHEMBL1107724 | 0.74 | GCK (0.49) | GCKPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885PTGS2 3837/4885HAO1 470/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885PTGS2 3999/4885HAO1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.